Pulmonary hypertension and chronic kidney disease: prevalence, pathophysiology and outcomes

Zeder, Katarina; Siew, Edward D.; Kovacs, Gabor; Brittain, Evan L.; Maron, Bradley A.

doi:10.1038/s41581-024-00857-7

Nat Rev Nephrol

2024

DOI: 10.1038/s41581-024-00857-7

|View full text |Cite

Pulmonary hypertension and chronic kidney disease: prevalence, pathophysiology and outcomes

Katarina Zeder,

Edward D. Siew,

Gabor Kovacs

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 134 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Pulmonary vasodilators in patients with advanced chronic kidney disease and pre‐capillary pulmonary hypertension—A case series

Leguizamon,

McLaren,

John

et al. 2024

Respirology Case Reports

View full text Add to dashboard Cite

Pulmonary hypertension (PH) is a prevalent complication among patients with chronic kidney disease (CKD). In these patients, pulmonary vasodilators may be useful but are underused. We describe a group of patients with precapillary PH and advanced CKD treated with pulmonary vasodilators. This was a case series of patients with CKD stage 4 and 5 and precapillary PH (isolated or combined) based on right heart catheterization (RHC) treated with pulmonary vasodilators from 2018 to 2023. Of 263 patients with isolated precapillary or combined PH and advanced CKD, only 17 (6%) were treated with pulmonary vasodilators; 53% (n = 9) with precapillary PH and 47% (n = 8) with combined PH. Most patients (94%, n = 16) received phosphodiesterase‐5 antagonists, while 12% (n = 2) received endothelin receptor antagonists. Adverse clinical outcomes were seen in 35% of patients within a year. The use of pulmonary vasodilator did not prevent adverse outcomes in patients with precapillary PH and advanced CKD.

show abstract

Pulmonary vasodilators in patients with advanced chronic kidney disease and pre‐capillary pulmonary hypertension—A case series

Leguizamon,

McLaren,

John

et al. 2024

Respirology Case Reports

View full text Add to dashboard Cite

show abstract

Association of arteriovenous fistulae with precapillary pulmonary hypertension – A single center retrospective analysis of invasive hemodynamic parameters

Malin,

Khan,

Manzano

et al. 2024

Heart & Lung

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Pulmonary hypertension and chronic kidney disease: prevalence, pathophysiology and outcomes

Cited by 2 publications

References 134 publications

Pulmonary vasodilators in patients with advanced chronic kidney disease and pre‐capillary pulmonary hypertension—A case series

Pulmonary vasodilators in patients with advanced chronic kidney disease and pre‐capillary pulmonary hypertension—A case series

Association of arteriovenous fistulae with precapillary pulmonary hypertension – A single center retrospective analysis of invasive hemodynamic parameters

Contact Info

Product

Resources

About